CSPG4 and neoplasm: Furthermore, CSPG4 targeting through a chimeric human/dog (HuDo)-CSPG4 DNA vaccine has shown promising anti-tumor activity in highly translational comparative OSA models, including human xenograft mouse models and canine patients with spontaneous OSA [19].